Showed an initial Phase 1 trial of PX-12 patients in 38 with advanced metastatic cancer that PX-12 was well tolerated and a reduction in the plasma concentrations of thioredoxin , which correlated significantly with an increased survival rate of the patients. Fifteen of the 38 patients achieved stable disease of up to 322 days. Oncothyreon is also currently a Phase 2 trial have PX-12 as a 3-hour infusion given daily for five days of a 21 day cycle in patients with advanced pancreatic cancer that has progressed on gemcitabine or gemcitabine – containing regimen http://bluepill.net .
Although Oncothyreon believes that any forward-looking statements contained are reasonable, it can give no assurance that these expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of of the risks and uncertainties associated with Oncothyreon, you are prompted, the official corporate documents check Oncothyreon Inc. With the securities regulatory authorities in the U.S. And Canada with the SEC and on SEDAR. Oncothyreon is under no obligation update or alter forward-looking statements, whether as a result of any other new information, future events or otherwise.
On Ascenta TherapeuticsAscenta Therapeutics, is detected a privately held, clinical-stage biopharmaceutical companies, and new medicines are developed for treating cancer. The company has in Malvern, Pennsylvania, and has a preclinical research Shanghai, Seine technology, from both National Institute of Health and the laboratory of Dr. Shaomeng Wang at the the University of Michigan will be licensed, focused on discovery of molecules that objective proteins that to extend survival of the cells.
More than 490,000 Arab Americans in the southeast of Michigan, the greatest population somewhere in outside the Middle East located for the study, researchers in Arab – American female in town Detroit, a. Southeast the Detroit suburb of in which Arab Americans comprises a third of 100,000 population.